Mylan Wins Motion to Enjoin GlaxoSmithKline from Providing Paroxetine CR to Apotex; Apotex Can No Longer Supply Authorized Gene

 Mylan Wins Motion to Enjoin GlaxoSmithKline from Providing Paroxetine CR to
        Apotex; Apotex Can No Longer Supply Authorized Generic Product

PR Newswire

PITTSBURGH, July 17, 2014

PITTSBURGH, July 17, 2014 /PRNewswire/ --Mylan Inc. (Nasdaq: MYL) today
announced that the U.S. District Court for the District of New Jersey granted
its motion for a permanent injunction against GlaxoSmithKline (GSK) in
relation to Paroxetine CR, the generic version of GSK's Paxil^® CR. GSK is now
precluded from supplying product to Apotex, which marketed the product as an
authorized generic. Mylan had previously been awarded damages in the amount of
$106,700,000 by the District Court after a favorable jury verdict in March
2014.

Mylan

In addition, the District Court awarded Mylan prejudgment interest and
permitted it to take an accounting so that Mylan can determine the amount of
additional damages it has suffered since Sept. 30, 2013 as a result of GSK's
ongoing breach. All of GSK's post-trial motions were denied.

Mylan is the only company to have successfully developed an FDA-approved
generic version of this product.

Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service excellence a habit; do what's right, not what's easy;
and impact the future through passionate global leadership. We offer a growing
portfolio of more than 1,300 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral therapies,
upon which approximately 40% of HIV/AIDS patients in developing countries
depend. We also operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in approximately 140 countries and
territories. Our workforce of more than 20,000 people is dedicated to
improving the customer experience and increasing pharmaceutical access to
consumers around the world. But don't take our word for it. See for yourself.
See inside. mylan.com

Logo - http://photos.prnewswire.com/prnh/20140423/77793

SOURCE Mylan Inc.

Website: http://www.mylan.com
Contact: Nina Devlin (Media): 724.514.1968; Kris King (Investors),
724.514.1813
 
Press spacebar to pause and continue. Press esc to stop.